Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines
| Autor: | Corinne Carpenter, Patrick Lenehan, Nikhil Kayal, Deeksha Doddahonnaiah, John Halamka, Gregory J. Gores, Andrew D. Badley, Eli Silvert, Katie Carlson, Anna Metzger, Venky Soundararajan, Colin Pawlowski, Melanie D. Swift, AJ Venkatakrishnan, Samir Awasthi, Eshwan Ramudu, John C. O’Horo, Abinash Virk, Amy W. Williams, Vineet Agarwal, Reid McMurry, Ajit Rajasekharan, Tyler Wagner, Gabi Berner, Arjun Puranik, Praveen Anand |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
myalgia
medicine.medical_specialty COVID-19 Vaccines Side effect Drug-Related Side Effects and Adverse Reactions real world analysis Mass Vaccination mRNA-1273 Medicine Humans vaccine safety RNA Messenger Adverse effect BNT162 Vaccine Retrospective Studies propensity score matching business.industry SARS-CoV-2 United States Food and Drug Administration COVID-19 Retrospective cohort study Clinical Advances General Medicine Emergency department United States Vaccination Clinical trial Tolerability Emergency medicine BNT162b2 medicine.symptom business |
| Zdroj: | Med (New York, N.y.) |
| ISSN: | 2666-6340 |
| Popis: | Background As the coronavirus disease 2019 (COVID-19) vaccination campaign unfolds, it is important to continuously assess the real-world safety of Food and Drug Administration (FDA)-authorized vaccines. Curation of large-scale electronic health records (EHRs) enables near-real-time safety evaluations that were not previously possible. Methods In this retrospective study, we deployed deep neural networks over a large EHR system to automatically curate the adverse effects mentioned by physicians in over 1.2 million clinical notes between December 1, 2020 and April 20, 2021. We compared notes from 68,266 individuals who received at least one dose of BNT162b2 (n = 51,795) or mRNA-1273 (n = 16,471) to notes from 68,266 unvaccinated individuals who were matched by demographic, geographic, and clinical features. Findings Individuals vaccinated with BNT162b2 or mRNA-1273 had a higher rate of return to the clinic, but not the emergency department, after both doses compared to unvaccinated controls. The most frequently documented adverse effects within 7 days of each vaccine dose included myalgia, headache, and fatigue, but the rates of EHR documentation for each side effect were remarkably low compared to those derived from active solicitation during clinical trials. Severe events, including anaphylaxis, facial paralysis, and cerebral venous sinus thrombosis, were rare and occurred at similar frequencies in vaccinated and unvaccinated individuals. Conclusions This analysis of vaccine-related adverse effects from over 1.2 million EHR notes of more than 130,000 individuals reaffirms the safety and tolerability of the FDA-authorized mRNA COVID-19 vaccines in practice. Funding This study was funded by nference. Graphical abstract Context and significance This is a study of the mRNA COVID-19 vaccines developed by Pfizer/BioNTech and Moderna. Although these vaccines have been shown to be safe and tolerated in clinical trials, it is important to confirm their safety profiles in practice. The results from this study show that individuals receiving these vaccines are likely to experience muscle and joint soreness, but they are not more likely to seek out emergent clinical care or experience severe medical events than unvaccinated individuals. As one of the largest real-world safety studies of COVID-19 vaccines to date, these data reinforce that we should continue expanding efforts to deliver more vaccines with high confidence in their safety. McMurry et al. assess the real-world safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines. Using natural language processing, they compare the rates of specified adverse effects between 68,266 vaccinated individuals and 68,266 matched unvaccinated individuals. They find that both vaccines are safe and tolerated in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|